AU2003295343A1 - Uses of human zven proteins and polynucleotides - Google Patents

Uses of human zven proteins and polynucleotides

Info

Publication number
AU2003295343A1
AU2003295343A1 AU2003295343A AU2003295343A AU2003295343A1 AU 2003295343 A1 AU2003295343 A1 AU 2003295343A1 AU 2003295343 A AU2003295343 A AU 2003295343A AU 2003295343 A AU2003295343 A AU 2003295343A AU 2003295343 A1 AU2003295343 A1 AU 2003295343A1
Authority
AU
Australia
Prior art keywords
polynucleotides
human zven
zven proteins
proteins
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003295343A
Other languages
English (en)
Other versions
AU2003295343A8 (en
Inventor
Chung Chan
Richard M. Garcia
Susan D. Holderman
Stephen R. Jaspers
Katherine E. Lewis
Penny J. Thompson
Robert R. West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of AU2003295343A1 publication Critical patent/AU2003295343A1/en
Publication of AU2003295343A8 publication Critical patent/AU2003295343A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
AU2003295343A 2002-10-07 2003-10-07 Uses of human zven proteins and polynucleotides Abandoned AU2003295343A1 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
USNOTGIVEN 1997-12-03
US41671802P 2002-10-07 2002-10-07
US41671902P 2002-10-07 2002-10-07
US60/416,719 2002-10-07
US60/416,718 2002-10-07
US43411602P 2002-12-16 2002-12-16
US43391802P 2002-12-16 2002-12-16
US60/434,116 2002-12-16
US60/433,918 2002-12-16
US50861403P 2003-10-03 2003-10-03
US50860303P 2003-10-03 2003-10-03
PCT/US2003/031714 WO2004031367A2 (en) 2002-10-07 2003-10-07 Uses of human zven proteins and polynucleotides

Publications (2)

Publication Number Publication Date
AU2003295343A1 true AU2003295343A1 (en) 2004-04-23
AU2003295343A8 AU2003295343A8 (en) 2004-04-23

Family

ID=32097184

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003295343A Abandoned AU2003295343A1 (en) 2002-10-07 2003-10-07 Uses of human zven proteins and polynucleotides
AU2003279841A Abandoned AU2003279841A1 (en) 2002-10-07 2003-10-07 Uses of human zven antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003279841A Abandoned AU2003279841A1 (en) 2002-10-07 2003-10-07 Uses of human zven antagonists

Country Status (6)

Country Link
US (16) US7291589B2 (https=)
EP (1) EP1558287A4 (https=)
JP (1) JP2006514683A (https=)
AU (2) AU2003295343A1 (https=)
CA (2) CA2500772A1 (https=)
WO (2) WO2004031367A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
KR100618495B1 (ko) 1998-10-06 2006-08-31 마크 아론 에말파브 섬유상의 진균성 숙주 영역에서의 형질전환 시스템:크리소스포륨속에서
US6485938B1 (en) * 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
WO2004032851A2 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Screening and therapeutic methods relating to neurogenesis
JP2006514683A (ja) * 2002-10-07 2006-05-11 ザイモジェネティクス，インコーポレイティド ヒトｚｖｅｎアンタゴニストの使用
JP4912144B2 (ja) * 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
KR20080006564A (ko) 2005-03-24 2008-01-16 얀센 파마슈티카 엔.브이. 프로키네티신 1 수용체 길항제
JP2008537548A (ja) * 2005-03-24 2008-09-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ プロキネチシン１受容体
CA2622575A1 (en) 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use
WO2007079163A2 (en) 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 1 receptor antagonists
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
WO2008121046A1 (en) * 2007-03-29 2008-10-09 Forskarpatent I Syd Ab Improvement of gastric emptying in patients suffering from diabetes mellitus
US20100286021A1 (en) * 2007-09-25 2010-11-11 Qun-Yong Zhou Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders
US11650213B2 (en) * 2015-03-30 2023-05-16 Entvantage Diagnostics, Inc. Devices and assays for diagnosis of viral and bacterial infections

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756479A (en) * 1987-04-06 1988-07-12 Lazenby Iii George I Flush hydrant
US5294630A (en) * 1992-07-07 1994-03-15 Eli Lilly And Company Treatment of inflammatory bowel disease
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US5891720A (en) * 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
JP2001512013A (ja) 1997-08-01 2001-08-21 ジェンセット 前立腺に発現される分泌タンパク質の５’ｅｓｔ
CA2328895A1 (en) 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
AU5151100A (en) 1999-05-19 2000-12-05 Incyte Genomics, Inc. Extracellular signaling molecules
US6485938B1 (en) * 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
WO2001036465A2 (en) * 1999-11-16 2001-05-25 Zymogenetics, Inc. Human zven proteins
CA2394749A1 (en) * 1999-12-28 2001-07-05 Pharmacia & Upjohn Company G protein-coupled receptors
EP1302542B1 (en) 2000-07-18 2007-06-13 Takeda Pharmaceutical Company Limited Novel physiologically active peptide and use thereof
EP1506971A1 (en) * 2000-11-03 2005-02-16 The Regents of the University of California Prokineticin polypeptides, related compositions and methods
JP2004532609A (ja) 2000-11-03 2004-10-28 ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア プロキネチシンポリペプチド、関連組成物および方法
US6671555B2 (en) * 2001-04-27 2003-12-30 Medtronic, Inc. Closed loop neuromodulation for suppression of epileptic activity
AU2002359351A1 (en) 2001-11-02 2003-05-19 Nuvelo, Inc. Methods and materials relating to prokineticin-like polypeptides and polynucleotides
EP1581648A2 (en) * 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
JP2006514683A (ja) * 2002-10-07 2006-05-11 ザイモジェネティクス，インコーポレイティド ヒトｚｖｅｎアンタゴニストの使用
WO2004065419A1 (ja) 2003-01-22 2004-08-05 Takeda Pharmaceutical Company Limited 抗体およびその用途
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
US7115560B2 (en) * 2003-03-25 2006-10-03 The Regents Of The University Of California Methods for modulating gastric secretion using prokineticin receptor antagonists
US20070014799A1 (en) 2003-10-22 2007-01-18 Takeda Pharmaceutical Company Limited Antibody and use of the same
CA2622575A1 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use

Also Published As

Publication number Publication date
US20070053907A1 (en) 2007-03-08
US7205110B2 (en) 2007-04-17
US7291589B2 (en) 2007-11-06
WO2004031367A2 (en) 2004-04-15
US20040156842A1 (en) 2004-08-12
US20090312258A1 (en) 2009-12-17
WO2004032850A3 (en) 2005-03-17
US20070049526A1 (en) 2007-03-01
AU2003279841A1 (en) 2004-05-04
US20070053908A1 (en) 2007-03-08
US20070092912A1 (en) 2007-04-26
WO2004031367A3 (en) 2004-07-22
AU2003295343A8 (en) 2004-04-23
US20090312257A1 (en) 2009-12-17
EP1558287A4 (en) 2009-07-08
AU2003279841A8 (en) 2004-05-04
CA2500772A1 (en) 2004-04-22
US20070078259A1 (en) 2007-04-05
US20070065404A1 (en) 2007-03-22
US20070087414A1 (en) 2007-04-19
US7629445B2 (en) 2009-12-08
US20070048778A1 (en) 2007-03-01
US20070048258A1 (en) 2007-03-01
US20070065403A1 (en) 2007-03-22
EP1558287A2 (en) 2005-08-03
JP2006514683A (ja) 2006-05-11
US20090312256A1 (en) 2009-12-17
US7592312B2 (en) 2009-09-22
US20040162238A1 (en) 2004-08-19
CA2500962A1 (en) 2004-04-15
US20070065405A1 (en) 2007-03-22
US7531311B2 (en) 2009-05-12
WO2004032850A2 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2001286171A1 (en) Human cDNAs and proteins and uses thereof
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2003222347A1 (en) Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof
AU2003294217A1 (en) Human polypeptides encoded by polynucleotides and methods of their use
AU2003295343A1 (en) Uses of human zven proteins and polynucleotides
AU2003276937A1 (en) Vegetable protein preparations and use thereof
AU2003280084A1 (en) Protein arrays and uses thereof
AU2003226899A1 (en) Human diabetes-mediating proteins
AU2002250386A1 (en) Expansin protein and polynucleotides and methods of use
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003298606A1 (en) Human polypeptides encoded by polynucleotides and methods of their use
AU2003252075A1 (en) Human immunosuppressive protein
AU2003284597A1 (en) Apoptosis-associated protein and use thereof
AUPR595601A0 (en) Hypoglycaemic peptides and methods of use thereof
AU2003274919A1 (en) Multifunctional context-activated protides and methods of use
AU2003280992A1 (en) Novel proteins and use thereof
AU2003265867A1 (en) A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
AU2003292774A1 (en) Novel proteins and use thereof
EP1551440A4 (en) USES OF ZEN PROTEINS OF HUMAN ORIGIN AND ASSOCIATED POLYNUCLEOTIDES
AU2003235665A1 (en) Diagnostic and therapeutic uses of topors
AU2002345407A1 (en) Human cervical cancer 5 protooncogene and protein encoded therein
AUPS243002A0 (en) Therapeutic target and uses thereof
AU2003229752A1 (en) Human rhomboid-related protein
AU2003260487A1 (en) Novel pancortin-pablo protein interactions and methods of use thereof
EP1549951A4 (en) SEMAPHORIN-LIKE PROTEINS AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase